• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025

    9/16/25 4:05:00 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NBIX alert in real time by email
    • Additional Data from SAVITRI™ Study Expand on Top-Line Results Announced in April 2024
    • SAVITRI Poster Presentation Chosen as Finalist for Psych Congress Poster Awards

    SAN DIEGO, Sept. 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that it will present new data from the Phase 2 SAVITRI study of osavampator in adults with major depressive disorder at Psych Congress 2025, taking place September 17-21 in San Diego. The results will be shared on September 18, from 4:30 pm – 5:45 pm PT as part of a poster presentation session entitled "Latest Discoveries & Emerging Trends in MDD."

    (PRNewsfoto/Neurocrine Biosciences, Inc.)

    Osavampator (NBI-1065845) is an investigational selective positive allosteric modulator of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA-PAM) in development as a potential adjunctive treatment for adults with major depressive disorder (MDD) who have an inadequate response to oral antidepressant treatment.

    "The expanded data we will share at Psych Congress from our Phase 2 SAVITRI study represent an important step forward in understanding and addressing major depressive disorder," said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. "We are confident in our osavampator program and its potential to be a first-in-class treatment."

    Following the announcement of positive top-line data from the Phase 2 SAVITRI study, Neurocrine initiated a Phase 3 registrational program of osavampator in January 2025, which includes five studies that are currently active and enrolling. For more information about the Phase 3 osavampator studies, please visit: ClinicalTrials.gov.

    Neurocrine will present the following posters at Psych Congress, which will be displayed on Friday, September 19 from 1:30 pm – 3:00 pm PT and 6:00 pm – 7:15 pm PT and on Saturday, September 20 from 1:30 pm – 3:00 pm PT:

    • Osavampator (NBI-1065845/TAK-653) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Depression Severity and is Well Tolerated in Adults with Major Depressive Disorder: Phase 2 SAVITRI Results (Poster #33)
      • Finalist for Psych Congress Poster Awards. Nominated Posters on Display Saturday, September 20 from 6:00 pm – 7:15 pm PT.
    • Osavampator: A Selective Positive Allosteric Modulator of the AMPA Receptor (AMPA-PAM) in Development for the Treatment of Major Depressive Disorder (Poster #34)
    • The Functional Impact of Major Depressive Disorder on Patients' Daily Lives: A Qualitative Investigation of Patient and Clinician Perspectives (Poster #20)
      • Finalist for Psych Congress Poster Awards. Nominated Posters on Display Saturday, September 20 from 6:00 pm – 7:15 pm PT.
    • Once-Daily Valbenazine Improves the Impacts and Symptoms of Tardive Dyskinesia Regardless of Psychiatric Diagnosis: Results from the Phase 4 KINECT-PRO™ Study (Poster #152)
    • Once-Daily Valbenazine Improves the Impacts of Tardive Dyskinesia (TD) in Patients Who Met a Threshold for TD Remission: Post Hoc Analyses of Patient-Reported Outcomes from KINECT-PRO (Poster #158)
    • Valbenazine Improves Physical, Social, and Emotional Impacts on the Tardive Dyskinesia Impact Scale (TDIS™): Post Hoc Analyses of KINECT-PRO Data (Poster #160)
    • Estimation of the Minimal Clinically Important Difference (MCID) and Longitudinal Change in the Tardive Dyskinesia Impact Scale (TDIS), a Validated, Tardive Dyskinesia-Specific, Patient-Reported Outcome Measure (Poster #98)
    • Physical, Mental, and Socioemotional Functional Improvement Following Valbenazine Treatment for Tardive Dyskinesia: a Case Series (Poster #84)
    • Once-Daily Valbenazine for the Treatment of Tardive Dyskinesia in Elderly Adults and Other Special Populations (Poster #186)
    • Valbenazine Improves Tardive Dyskinesia in Patients Regardless of Ethnicity or Race: Post Hoc Analyses of Long-Term Data from the KINECT® 4 Study (Poster #150)
    • A Qualitative, Interview-based Study of Patient, Caregiver, and Prescriber Rankings of Functional Outcome Improvements in Schizophrenia (Poster #108)

    About Osavampator and the Phase 2 SAVITRI Study

    Osavampator (NBI-1065845) is an investigational potential first-in-class selective positive allosteric modulator of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA-PAM) in development as a potential adjunctive treatment for adults with major depressive disorder (MDD) who have an inadequate response to oral antidepressant treatment. Neurocrine received an exclusive license to osavampator from Takeda Pharmaceutical Company Limited for all indications in all territories worldwide except Japan.

    The Phase 2 SAVITRI study was a double-blind, placebo-controlled study designed to assess the efficacy and safety of investigational osavampator in adult subjects with MDD. The study enrolled 183 adults with a primary diagnosis of MDD who had an inadequate response to current antidepressant treatment.

    About Major Depressive Disorder 

    Major depressive disorder is a serious disorder characterized by a persistently depressed mood, loss of interest, poor concentration, and decreased energy, among other symptoms. According to the World Health Organization, MDD is one of the leading causes of disability, is a serious condition that presents an increased risk of suicide and self-harm and is associated with increased all-cause mortality. More than 21 million people in the U.S. live with MDD, and about half of patients do not get enough relief from their first antidepressant.

    About Neurocrine Biosciences, Inc. 

    Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X and Facebook. (*in collaboration with AbbVie)

    The NEUROCRINE BIOSCIENCES Logo, NEUROCRINE, YOU DESERVE BRAVE SCIENCE, INGREZZA and KINECT are registered trademarks of Neurocrine Biosciences, Inc. SAVITRI, TDIS and KINECT-PRO are trademarks of Neurocrine Biosciences, Inc.

    Forward-Looking Statements

    In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the clinical results from, and our future development plans with respect to, osavampator (NBI-1065845), the therapeutic potential and clinical benefits or safety profile of osavampator, and the potential benefits to be derived from certain of our products. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: data that we report may change following a more comprehensive review of the data related to the clinical study and such data may not accurately reflect the complete results of the clinical study; risks that clinical development activities may not be initiated or completed on time or at all, or may be delayed for regulatory, manufacturing or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials; risks that regulatory submissions for our product candidates may not occur or be submitted in a timely manner; our future financial and operating performance; risks associated with our dependence on third parties for development, manufacturing and commercialization activities for our products and product candidates and our ability to manage these third parties; risks that the FDA or other regulatory authorities may make adverse decisions regarding our products or product candidates; risks that the potential benefits of the agreements with our collaboration partners may never be realized; risks that our products and/or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks associated with U.S. federal or state legislative or regulatory and/or policy efforts which may result in, among other things, an adverse impact on our revenues or potential revenue; risks associated with potential generic entrants for our products; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2025. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law.

    © 2025 Neurocrine Biosciences, Inc. All Rights Reserved

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-new-data-from-phase-2-study-of-osavampator-in-adults-with-major-depressive-disorder-at-38th-annual-psych-congress-2025-302558274.html

    SOURCE Neurocrine Biosciences, Inc.

    Get the next $NBIX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NBIX

    DatePrice TargetRatingAnalyst
    7/21/2025$163.00Buy
    Truist
    7/10/2025$182.00Buy
    Goldman
    4/15/2025$138.00Hold → Buy
    Needham
    4/14/2025$137.00Sector Perform → Outperform
    RBC Capital Mkts
    2/11/2025$138.00Hold
    Deutsche Bank
    10/10/2024$155.00Outperform
    Raymond James
    8/29/2024$131.00 → $159.00Neutral → Overweight
    Piper Sandler
    4/24/2024$140.00 → $170.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $NBIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Onyia Jude gifted 1,470 shares, decreasing direct ownership by 10% to 13,703 units (SEC Form 4)

    4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

    9/4/25 5:28:48 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sherwin Stephen A gifted 1,000 shares, decreasing direct ownership by 7% to 12,542 units (SEC Form 4)

    4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

    9/3/25 6:47:36 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Gorman Kevin Charles sold $13,440,281 worth of shares (106,322 units at $126.41) and exercised 106,322 shares at a strike of $35.99 (SEC Form 4)

    4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

    8/11/25 4:55:16 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NBIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Neurocrine Biosciences with a new price target

    Truist initiated coverage of Neurocrine Biosciences with a rating of Buy and set a new price target of $163.00

    7/21/25 8:37:42 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Goldman initiated coverage on Neurocrine Biosciences with a new price target

    Goldman initiated coverage of Neurocrine Biosciences with a rating of Buy and set a new price target of $182.00

    7/10/25 8:58:47 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neurocrine Biosciences upgraded by Needham with a new price target

    Needham upgraded Neurocrine Biosciences from Hold to Buy and set a new price target of $138.00

    4/15/25 7:52:35 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NBIX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 13, 2024 - FDA Approves New Treatment for Congenital Adrenal Hyperplasia

    For Immediate Release: December 13, 2024 Today, the U.S. Food and Drug Administration approved Crenessity (crinecerfont) to be used together with glucocorticoids (steroids) to control androgen (a testosterone-like hormone) levels in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).“Today’s approval provides an important advance for patients with classic con

    12/13/24 5:54:17 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NBIX
    SEC Filings

    View All

    SEC Form 10-Q filed by Neurocrine Biosciences Inc.

    10-Q - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)

    7/30/25 4:04:04 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neurocrine Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)

    7/30/25 4:02:54 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neurocrine Biosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)

    5/30/25 4:05:10 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NBIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden

    The KINECT-PRO™ analysis is the first and only of its kind to report both remission of tardive dyskinesia symptoms and associated improvements in patient-reported outcomes.Post-hoc analysis from KINECT-PRO demonstrated substantial symptomatic remission rates at Week 24, even earlier than previous studies have reported.Patients who achieved symptomatic remission had robust improvements across multiple patient-reported outcome measures after 24 weeks of INGREZZA treatment.SAN DIEGO, Sept. 23, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced new data from a post-hoc analysis of the Phase 4 KINECT-PRO™ open-label study confirming that robust rates of symptomatic re

    9/23/25 8:30:00 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder

    SAN DIEGO, Sept. 22, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the presentation of new data from the Phase 2 SAVITRI™ study, which showed statistically significant and clinically meaningful improvement in depression severity at Day 28 and Day 56 with once-daily oral administration of 1 mg osavampator (NBI-1065845). In recognition of the data presentation, Neurocrine was honored with the 2025 Poster Award at the 38th annual Psych Congress in San Diego. "Major depressive disorder is one of the most common mental health conditions, and up to

    9/22/25 8:30:00 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025

    Additional Data from SAVITRI™ Study Expand on Top-Line Results Announced in April 2024SAVITRI Poster Presentation Chosen as Finalist for Psych Congress Poster AwardsSAN DIEGO, Sept. 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that it will present new data from the Phase 2 SAVITRI study of osavampator in adults with major depressive disorder at Psych Congress 2025, taking place September 17-21 in San Diego. The results will be shared on September 18, from 4:30 pm – 5:45 pm PT as part of a poster presentation session entitled "Latest Discoveries & Emerging Trends in MDD."

    9/16/25 4:05:00 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NBIX
    Leadership Updates

    Live Leadership Updates

    View All

    Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer

    SAN DIEGO, June 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Lewis Choi as Chief Information Officer, effective June 9, 2025. Choi, an accomplished leader with 25 years of experience in information technology and artificial intelligence, will be responsible for driving the vision and long-term strategic direction of the company's technology initiatives. "Lewis is a proven global healthcare leader with a track record of utilizing technology to drive both cultural and technological change," said Matt Abernethy, Chief Finan

    6/9/25 4:05:00 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

    SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Matthew Abernethy, M.B.A., to its Board of Directors effective as of May 29, 2025. Mr. Abernethy brings to the Company over 15 years' experience in corporate finance and investor relations in the biotech and medical device industry. In addition, the Company announced that Timothy P. Coughlin stepped down from the Board of Directors, effective concurrently with Mr. Abernethy's appointment. "Mr. Aberne

    5/30/25 4:30:14 PM ET
    $FATE
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer

    Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas SAN DIEGO, April 4, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Sanjay Keswani, M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025. Dr. Keswani, an accomplished physician-scientist who has more than 20 years of pharmaceutical industry experience with broad R&D expertise in multiple therapeutic areas, will lead the clinical development and medical affairs activities at Neurocrine. Dr. Keswani succeeds Eiry W. Roberts, M.D., who has served as C

    4/4/25 8:00:00 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NBIX
    Financials

    Live finance-specific insights

    View All

    Neurocrine Biosciences Reports Second Quarter 2025 Financial Results

    Achieved Total Net Product Sales of $682 Million Representing 17% Year-Over-Year Growth INGREZZA® (valbenazine) Second-Quarter 2025 Net Product Sales of $624 Million and Narrows 2025 Net Product Sales Guidance to $2.5 - $2.55 Billion CRENESSITY® (crinecerfont) Second-Quarter 2025 Net Product Sales of $53 Million with 664 Total New Patient Enrollment Start Forms SAN DIEGO, July 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the second quarter ended June 30, 2025, and updated its 2025 financial guidance. "As we begin

    7/30/25 4:01:00 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results

    Conference Call and Webcast Scheduled for Wednesday, July 30 SAN DIEGO, July 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its second quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on July 30, 2025. The schedule for the press release and conference call / webcast is as follows: Q2 2025 Press Release: July 30, 2025 at 1:00 p.m. PT / 4:00 p.m. ETQ2 2025 Conference Call: July 30, 2025 at 1:30 p.m. PT / 4:30 p.m. ETDomestic Dial-In Number: 800-225-9448Internat

    7/9/25 4:01:00 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance

    INGREZZA® (valbenazine) First-Quarter 2025 Net Product Sales of $545 Million and Reaffirms 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion CRENESSITYTM (crinecerfont) First-Quarter 2025 Net Product Sales of $14.5 Million with 413 Total Patient Enrollment Start Forms Initiated Phase 3 Registrational Programs for Osavampator in Major Depressive Disorder and NBI-'568 in Schizophrenia to Position for Next Phase of Growth SAN DIEGO, May 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the first quarter ended March 31, 2025, and reaffirms its 2025 financial guidance.

    5/5/25 4:01:00 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NBIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Neurocrine Biosciences Inc.

    SC 13G - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

    10/17/24 9:54:01 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Neurocrine Biosciences Inc. (Amendment)

    SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

    2/9/23 11:27:44 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Neurocrine Biosciences Inc. (Amendment)

    SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

    2/14/22 2:34:19 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care